Company intelligence / Profile preview

Shanghai Baoji Pharmaceutical

Shanghai, Shanghai, China

Ownership: Private
Employees: ~348
Development stage: Other

Overview

Shanghai Baoji Pharmaceutical's lead product SJ02 (long-acting FSH-CTP) received NDA approval from the NMPA in China in August 2025 for controlled ovarian stimulation. The company successfully went public on the Hong Kong Stock Exchange in December 2025. Other core products, KJ103 (Ricefidase) and KJ017 (recombinant hyaluronidase), are currently in late-stage clinical trials or NDA registration phases.

Therapeutic areas: NephrologyWomen's HealthNeurologyInfectious DiseasesOncology
Modalities: Recombinant proteinRecombinant fusion proteinRecombinant proteaseBispecific monoclonal antibodyRecombinant enzymeSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Baoji Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Baoji Pharmaceutical.

Explore the full profile